Prizlon-cel CAR T cells for large B-cell lymphoma that returned after approved CAR T
Tests prizlon-cel in adults whose lymphoma came back after CAR T therapy.
Plain-language title generated from the registry record
Registry title: Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Key facts
- Where
- Gilbert and La Jolla, United StatesSee the 2 sites
- Phase
- Phase 2
Where in United States
- GilbertGilbert, United StatesNo longer taking part
- La JollaLa Jolla, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbelZeta Inc.
- Trial code
- NCT07875413
- Record updated
- 15 October 2026
- Original description
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapyRead full original descriptionShow less
A Multi-center, Phase 2 Clinical Study of an Autologous Anti-CD19/CD20 Chimeric Antigen Receptor T-Cell Therapy, Prizloncabtagene Autoleucel (Prizlon-cel), for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma
This Phase 2, multicenter, open-label study will evaluate the safety and efficacy of a single infusion of Prizloncel, an anti-CD19/CD20 chimeric antigen receptor T cells following lymphodepleting chemotherapy in participants with relapsed/refractory (r/r) diffuse large B-cell lymphoma post FDA approved, commercially available CAR T-cell therapy
Approximately 50 participants will undergo leukapheresis, lymphodepletion with fludarabine and cyclophosphamide, and infusion of Prizlon-cel. Participants will be followed for 24 months (approximately 2 years) to evaluate efficacy, safety, CAR T-cell persistence, pharmacokinetics/pharmacodynamics, and biomarkers. Long-term safety follow-up for gene therapy-related events will continue for up to 15 years following CAR T-cell infusion.
Inclusion: Able to sign and date the Informed Consent Form (ICF); ≥18 years of age, at the time of signing informed consent; Diagnosis of B-cell non-Hodgkin lymphoma (B-NHL), including the following neoplasms as defined by the 2022 WHO classification of lymphoid neoplasms:; Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); Primary mediastinal large B-cell lymphoma (PMBCL); Transformed follicular lymphoma (tFL) (Pathology report is required to clarify DLBCL rather than follicular lymphoma (FL) with local/minor progression to DLBCL); Diffuse large B-cell lymphoma/high-grade B-cell lymphoma with MYC and BCL2 rearrangements (DLBCL/HGBL-MYC/BCL2); High-grade B-cell lymphoma (HGBL), NOS; Follicular large B-cell lymphoma (FLBL) (At least 2 pathological diagnoses of follicular lymphoma grade 3B [FL3b] at different times are required, and the most recent pathology used for screening is FL3b or FLBL); R/R disease after ≥2 lines of standard therapy, including FDA approved, commercially available CAR T-cell therapy for at least 3 months since previous CAR T-cell therapy treatment; Measurable disease per the Lugano 2014 Classification.
Exclusion: Prior allogeneic hematopoietic stem cell transplantation (HSCT); Prior treatment with any investigational CAR T-cell therapy; ASCT within 12 weeks of leukapheresis.